Table 1. Binding and neutralization values for isolated RSV F-specific mAbs.
| Monoclonal antibody | IgG subclass | Light chain | Binding EC50 (ng/mL) |
Neutralization IC50 (ng/mL) |
|||||
|---|---|---|---|---|---|---|---|---|---|
| RSV A2 | RSV A2 SC-TM | RSV 18537 B DSCAV1 | RSV A2 | RSV Long | RSV 18537 B | RSV WV/401R | |||
| 2N6 | 1 | λ | 14 | 12 | 18 | 790 | 140 | 1,900 | 1,400 |
| 3M3 | 1 | λ | 20 | 13 | 20 | 14 | 3 | 16 | 29 |
| 6F18 | 1 | κ | 14 | 11 | 17 | 260 | 96 | 520 | 340 |
| 17E10 | 1 | λ | 11 | 13 | 15 | 2,200 | 334 | 1,000 | 15,00 |
| Control mAbs | |||||||||
| D25 | 1 | κ | > | 16 | > | 20 | 6.1 | 1,600 | 33 |
| motavizumab | 1 | κ | 96 | 69 | 66 | 60 | 7.5 | 25 | 40 |
| 101F | 1 | κ | 11 | 14 | 21 | 1,200 | 150 | 540 | 1,400 |
| 54G10 | 1 | κ | 19 | 130 | 44 | > | > | > | > |
EC50 values correspond to the concentration at which half-maximum signal was obtained in ELISA, based on optical density at 405 nm. Neutralization values were determined using a plaque-reduction assay, where the IC50 corresponds to the mAb concentration at which 50% plaque reduction was observed. > indicates no plaque reduction in neutralization assays or no signal detected below 25 μg/mL in ELISA binding assays. DS-Cav1 and SC-TM represent stabilized pre-fusion RSV F.